GlycoNex is Biotechnology in Taiwan that focus on glycosphingolipid antigen business. Founded in 2001. They cover business area such as GlycoNex Inc, cancer drug, glycosphingolipid antigen and human monoclonal antibody technology, various carbohydrate antigen, hybridoma, stability, application, ELISA, western blot, flow cytometry, TLC, IHC, antibody research service, its academic and industrial client, functional evaluation, antibody engineering, antibody characterization.
2001
( 23 years old in 2024 )
Glycosphingolipid Antigen
-
11F, No. 31-1
Lane 169, Kang-Ning Street
New Taipei, Hsi-Chih
Taiwan
Private
GlycoNex Inccancer drugglycosphingolipid antigen and human monoclonal antibody technologyvarious carbohydrate antigenhybridomastabilityapplicationELISAwestern blotflow cytometryTLCIHCantibody research serviceits academic and industrial clientfunctional evaluationantibody engineeringantibody characterization
* We use standard office opening hours in near GlycoNex's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
GlycoNex is Biotechnology business from Taiwan that founded in 2001 (23 years old in 2024), GlycoNex business is focusing on Glycosphingolipid Antigen.
GlycoNex headquarter office and corporate office address is located in 11F, No. 31-1 Lane 169, Kang-Ning Street New Taipei, Hsi-Chih Taiwan.
GlycoNex was founded in Taiwan.
In 2024, GlycoNex is currently focus on glycosphingolipid antigen sector.
Above is snippet of Google Trends for "glycosphingolipid antigen" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with GlycoNex, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
